Anaptysbio Stock Current Valuation
| ANAB Stock | USD 25.12 0.13 0.51% |
Valuation analysis of AnaptysBio helps investors to measure AnaptysBio's intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. As of November 29, 2024, Enterprise Value Over EBITDA is expected to decline to -4.1. In addition to that, Enterprise Value Multiple is expected to decline to -4.1. Fundamental drivers impacting AnaptysBio's valuation include:
Price Book 9.06 | Enterprise Value 350.7 M | Enterprise Value Ebitda (1.30) | Price Sales 13.3696 | Enterprise Value Revenue 6.1349 |
Overvalued
Today
Please note that AnaptysBio's price fluctuation is not too volatile at this time. Calculation of the real value of AnaptysBio is based on 3 months time horizon. Increasing AnaptysBio's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since AnaptysBio is currently traded on the exchange, buyers and sellers on that exchange determine the market value of AnaptysBio Stock. However, AnaptysBio's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 25.12 | Real 22.98 | Target 29.75 | Hype 25.12 | Naive 31.93 |
The real value of AnaptysBio Stock, also known as its intrinsic value, is the underlying worth of AnaptysBio Company, which is reflected in its stock price. It is based on AnaptysBio's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of AnaptysBio's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of AnaptysBio helps investors to forecast how AnaptysBio stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of AnaptysBio more accurately as focusing exclusively on AnaptysBio's fundamentals will not take into account other important factors: AnaptysBio Company Current Valuation Analysis
AnaptysBio's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current AnaptysBio Current Valuation | 350.75 M |
Most of AnaptysBio's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AnaptysBio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
AnaptysBio Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for AnaptysBio is extremely important. It helps to project a fair market value of AnaptysBio Stock properly, considering its historical fundamentals such as Current Valuation. Since AnaptysBio's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of AnaptysBio's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of AnaptysBio's interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, AnaptysBio has a Current Valuation of 350.75 M. This is 97.56% lower than that of the Biotechnology sector and 92.45% lower than that of the Health Care industry. The current valuation for all United States stocks is 97.89% higher than that of the company.
AnaptysBio Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AnaptysBio's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AnaptysBio could also be used in its relative valuation, which is a method of valuing AnaptysBio by comparing valuation metrics of similar companies.AnaptysBio is currently under evaluation in current valuation category among its peers.
AnaptysBio ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, AnaptysBio's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to AnaptysBio's managers, analysts, and investors.Environmental | Governance | Social |
AnaptysBio Fundamentals
| Return On Equity | -1.62 | ||||
| Return On Asset | -0.18 | ||||
| Profit Margin | (2.90) % | ||||
| Operating Margin | (0.76) % | ||||
| Current Valuation | 350.75 M | ||||
| Shares Outstanding | 30.43 M | ||||
| Shares Owned By Insiders | 1.73 % | ||||
| Shares Owned By Institutions | 98.27 % | ||||
| Number Of Shares Shorted | 6.71 M | ||||
| Price To Earning | 81.21 X | ||||
| Price To Book | 9.06 X | ||||
| Price To Sales | 13.37 X | ||||
| Revenue | 17.16 M | ||||
| Gross Profit | (78.51 M) | ||||
| EBITDA | (143.16 M) | ||||
| Net Income | (163.62 M) | ||||
| Cash And Equivalents | 442.15 M | ||||
| Cash Per Share | 15.66 X | ||||
| Total Debt | 17.81 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 22.79 X | ||||
| Book Value Per Share | 2.77 X | ||||
| Cash Flow From Operations | (120.8 M) | ||||
| Short Ratio | 12.16 X | ||||
| Earnings Per Share | (6.05) X | ||||
| Target Price | 54.36 | ||||
| Number Of Employees | 117 | ||||
| Beta | -0.24 | ||||
| Market Capitalization | 764.37 M | ||||
| Total Asset | 452.39 M | ||||
| Retained Earnings | (614.1 M) | ||||
| Working Capital | 369.39 M | ||||
| Current Asset | 297.84 M | ||||
| Current Liabilities | 16.6 M | ||||
| Net Asset | 452.39 M |
About AnaptysBio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AnaptysBio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AnaptysBio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AnaptysBio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether AnaptysBio offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AnaptysBio's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Anaptysbio Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Anaptysbio Stock:Check out AnaptysBio Piotroski F Score and AnaptysBio Altman Z Score analysis. For information on how to trade AnaptysBio Stock refer to our How to Trade AnaptysBio Stock guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AnaptysBio. If investors know AnaptysBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AnaptysBio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.05) | Revenue Per Share 2.086 | Quarterly Revenue Growth 8.047 | Return On Assets (0.18) | Return On Equity (1.62) |
The market value of AnaptysBio is measured differently than its book value, which is the value of AnaptysBio that is recorded on the company's balance sheet. Investors also form their own opinion of AnaptysBio's value that differs from its market value or its book value, called intrinsic value, which is AnaptysBio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AnaptysBio's market value can be influenced by many factors that don't directly affect AnaptysBio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AnaptysBio's value and its price as these two are different measures arrived at by different means. Investors typically determine if AnaptysBio is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AnaptysBio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.